Endothelin are the type of therapeutics that inhibits the action of endothelin and is thus effective for treating pulmonary arterial hypertension. This receptor, which plays a major role in regulating vascular tone, is found between the lumen and underlying media of the pulmonary vasculature. For patients suffering from the pulmonary hypertension, the body secrete high amount of endothelin that causes the blood vessels to be constricted and increase in the BP in the pulmonary arteries.

The global Endothelin Antagonists Therapeutics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Endothelin Antagonists Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Endothelin Antagonists Therapeutics.

Report Scope

The Endothelin Antagonists Therapeutics market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Endothelin Antagonists Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Endothelin Antagonists Therapeutics manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Endothelin Antagonists Therapeutics Market Report

Report Metric	Details
Report Name	Endothelin Antagonists Therapeutics Market
CAGR	5%
Segment by Type	Oral Parenteral
Segment by Application	Cardiovascular Diseases Scleroderma Other
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Gilead Sciences, Inc, Sun Pharmaceutical Industries Ltd, Lupin, Zydus Group, Endo International plc, Mylan NV, Teva Pharmaceutical Industries Ltd, Sigmapharm Laboratories , LLC, Alembic Pharmaceuticals Limited, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, AstraZeneca, Johnsons & Johnsons Private limited, GSK Plc
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Endothelin Antagonists Therapeutics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Endothelin Antagonists Therapeutics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Endothelin Antagonists Therapeutics Market report?

Ans: The main players in the Endothelin Antagonists Therapeutics Market are Gilead Sciences, Inc, Sun Pharmaceutical Industries Ltd, Lupin, Zydus Group, Endo International plc, Mylan NV, Teva Pharmaceutical Industries Ltd, Sigmapharm Laboratories , LLC, Alembic Pharmaceuticals Limited, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, AstraZeneca, Johnsons & Johnsons Private limited, GSK Plc

What are the Application segmentation covered in the Endothelin Antagonists Therapeutics Market report?

Ans: The Applications covered in the Endothelin Antagonists Therapeutics Market report are Cardiovascular Diseases, Scleroderma, Other

What are the Type segmentation covered in the Endothelin Antagonists Therapeutics Market report?

Ans: The Types covered in the Endothelin Antagonists Therapeutics Market report are Oral, Parenteral

1 Endothelin Antagonists Therapeutics Market Overview

1.1 Product Overview and Scope of Endothelin Antagonists Therapeutics

1.2 Endothelin Antagonists Therapeutics Segment by Type

1.2.1 Global Endothelin Antagonists Therapeutics Market Value Comparison by Type (2024-2030)

1.2.2 Oral

1.2.3 Parenteral

1.3 Endothelin Antagonists Therapeutics Segment by Application

1.3.1 Global Endothelin Antagonists Therapeutics Market Value by Application: (2024-2030)

1.3.2 Cardiovascular Diseases

1.3.3 Scleroderma

1.3.4 Other

1.4 Global Endothelin Antagonists Therapeutics Market Size Estimates and Forecasts

1.4.1 Global Endothelin Antagonists Therapeutics Revenue 2019-2030

1.4.2 Global Endothelin Antagonists Therapeutics Sales 2019-2030

1.4.3 Global Endothelin Antagonists Therapeutics Market Average Price (2019-2030)

1.5 Assumptions and Limitations

2 Endothelin Antagonists Therapeutics Market Competition by Manufacturers

2.1 Global Endothelin Antagonists Therapeutics Sales Market Share by Manufacturers (2019-2024)

2.2 Global Endothelin Antagonists Therapeutics Revenue Market Share by Manufacturers (2019-2024)

2.3 Global Endothelin Antagonists Therapeutics Average Price by Manufacturers (2019-2024)

2.4 Global Endothelin Antagonists Therapeutics Industry Ranking 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Endothelin Antagonists Therapeutics, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Endothelin Antagonists Therapeutics, Product Type & Application

2.7 Endothelin Antagonists Therapeutics Market Competitive Situation and Trends

2.7.1 Endothelin Antagonists Therapeutics Market Concentration Rate

2.7.2 The Global Top 5 and Top 10 Largest Endothelin Antagonists Therapeutics Players Market Share by Revenue

2.7.3 Global Endothelin Antagonists Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

2.8 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Endothelin Antagonists Therapeutics Retrospective Market Scenario by Region

3.1 Global Endothelin Antagonists Therapeutics Market Size by Region: 2019 Versus 2023 Versus 2030

3.2 Global Endothelin Antagonists Therapeutics Global Endothelin Antagonists Therapeutics Sales by Region: 2019-2030

3.2.1 Global Endothelin Antagonists Therapeutics Sales by Region: 2019-2024

3.2.2 Global Endothelin Antagonists Therapeutics Sales by Region: 2025-2030

3.3 Global Endothelin Antagonists Therapeutics Global Endothelin Antagonists Therapeutics Revenue by Region: 2019-2030

3.3.1 Global Endothelin Antagonists Therapeutics Revenue by Region: 2019-2024

3.3.2 Global Endothelin Antagonists Therapeutics Revenue by Region: 2025-2030

3.4 North America Endothelin Antagonists Therapeutics Market Facts & Figures by Country

3.4.1 North America Endothelin Antagonists Therapeutics Market Size by Country: 2019 VS 2023 VS 2030

3.4.2 North America Endothelin Antagonists Therapeutics Sales by Country (2019-2030)

3.4.3 North America Endothelin Antagonists Therapeutics Revenue by Country (2019-2030)

3.4.4 United States

3.4.5 Canada

3.5 Europe Endothelin Antagonists Therapeutics Market Facts & Figures by Country

3.5.1 Europe Endothelin Antagonists Therapeutics Market Size by Country: 2019 VS 2023 VS 2030

3.5.2 Europe Endothelin Antagonists Therapeutics Sales by Country (2019-2030)

3.5.3 Europe Endothelin Antagonists Therapeutics Revenue by Country (2019-2030)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Endothelin Antagonists Therapeutics Market Facts & Figures by Country

3.6.1 Asia Pacific Endothelin Antagonists Therapeutics Market Size by Country: 2019 VS 2023 VS 2030

3.6.2 Asia Pacific Endothelin Antagonists Therapeutics Sales by Country (2019-2030)

3.6.3 Asia Pacific Endothelin Antagonists Therapeutics Revenue by Country (2019-2030)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America Endothelin Antagonists Therapeutics Market Facts & Figures by Country

3.7.1 Latin America Endothelin Antagonists Therapeutics Market Size by Country: 2019 VS 2023 VS 2030

3.7.2 Latin America Endothelin Antagonists Therapeutics Sales by Country (2019-2030)

3.7.3 Latin America Endothelin Antagonists Therapeutics Revenue by Country (2019-2030)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Endothelin Antagonists Therapeutics Market Facts & Figures by Country

3.8.1 Middle East and Africa Endothelin Antagonists Therapeutics Market Size by Country: 2019 VS 2023 VS 2030

3.8.2 Middle East and Africa Endothelin Antagonists Therapeutics Sales by Country (2019-2030)

3.8.3 Middle East and Africa Endothelin Antagonists Therapeutics Revenue by Country (2019-2030)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Endothelin Antagonists Therapeutics Sales by Type (2019-2030)

4.1.1 Global Endothelin Antagonists Therapeutics Sales by Type (2019-2024)

4.1.2 Global Endothelin Antagonists Therapeutics Sales by Type (2025-2030)

4.1.3 Global Endothelin Antagonists Therapeutics Sales Market Share by Type (2019-2030)

4.2 Global Endothelin Antagonists Therapeutics Revenue by Type (2019-2030)

4.2.1 Global Endothelin Antagonists Therapeutics Revenue by Type (2019-2024)

4.2.2 Global Endothelin Antagonists Therapeutics Revenue by Type (2025-2030)

4.2.3 Global Endothelin Antagonists Therapeutics Revenue Market Share by Type (2019-2030)

4.3 Global Endothelin Antagonists Therapeutics Price by Type (2019-2030)

5 Segment by Application

5.1 Global Endothelin Antagonists Therapeutics Sales by Application (2019-2030)

5.1.1 Global Endothelin Antagonists Therapeutics Sales by Application (2019-2024)

5.1.2 Global Endothelin Antagonists Therapeutics Sales by Application (2025-2030)

5.1.3 Global Endothelin Antagonists Therapeutics Sales Market Share by Application (2019-2030)

5.2 Global Endothelin Antagonists Therapeutics Revenue by Application (2019-2030)

5.2.1 Global Endothelin Antagonists Therapeutics Revenue by Application (2019-2024)

5.2.2 Global Endothelin Antagonists Therapeutics Revenue by Application (2025-2030)

5.2.3 Global Endothelin Antagonists Therapeutics Revenue Market Share by Application (2019-2030)

5.3 Global Endothelin Antagonists Therapeutics Price by Application (2019-2030)

6 Key Companies Profiled

6.1 Gilead Sciences, Inc

6.1.1 Gilead Sciences, Inc Corporation Information

6.1.2 Gilead Sciences, Inc Description and Business Overview

6.1.3 Gilead Sciences, Inc Endothelin Antagonists Therapeutics Sales, Revenue and Gross Margin (2019-2024)

6.1.4 Gilead Sciences, Inc Endothelin Antagonists Therapeutics Product Portfolio

6.1.5 Gilead Sciences, Inc Recent Developments/Updates

6.2 Sun Pharmaceutical Industries Ltd

6.2.1 Sun Pharmaceutical Industries Ltd Corporation Information

6.2.2 Sun Pharmaceutical Industries Ltd Description and Business Overview

6.2.3 Sun Pharmaceutical Industries Ltd Endothelin Antagonists Therapeutics Sales, Revenue and Gross Margin (2019-2024)

6.2.4 Sun Pharmaceutical Industries Ltd Endothelin Antagonists Therapeutics Product Portfolio

6.2.5 Sun Pharmaceutical Industries Ltd Recent Developments/Updates

6.3 Lupin

6.3.1 Lupin Corporation Information

6.3.2 Lupin Description and Business Overview

6.3.3 Lupin Endothelin Antagonists Therapeutics Sales, Revenue and Gross Margin (2019-2024)

6.3.4 Lupin Endothelin Antagonists Therapeutics Product Portfolio

6.3.5 Lupin Recent Developments/Updates

6.4 Zydus Group

6.4.1 Zydus Group Corporation Information

6.4.2 Zydus Group Description and Business Overview

6.4.3 Zydus Group Endothelin Antagonists Therapeutics Sales, Revenue and Gross Margin (2019-2024)

6.4.4 Zydus Group Endothelin Antagonists Therapeutics Product Portfolio

6.4.5 Zydus Group Recent Developments/Updates

6.5 Endo International plc

6.5.1 Endo International plc Corporation Information

6.5.2 Endo International plc Description and Business Overview

6.5.3 Endo International plc Endothelin Antagonists Therapeutics Sales, Revenue and Gross Margin (2019-2024)

6.5.4 Endo International plc Endothelin Antagonists Therapeutics Product Portfolio

6.5.5 Endo International plc Recent Developments/Updates

6.6 Mylan NV

6.6.1 Mylan NV Corporation Information

6.6.2 Mylan NV Description and Business Overview

6.6.3 Mylan NV Endothelin Antagonists Therapeutics Sales, Revenue and Gross Margin (2019-2024)

6.6.4 Mylan NV Endothelin Antagonists Therapeutics Product Portfolio

6.6.5 Mylan NV Recent Developments/Updates

6.7 Teva Pharmaceutical Industries Ltd

6.6.1 Teva Pharmaceutical Industries Ltd Corporation Information

6.6.2 Teva Pharmaceutical Industries Ltd Description and Business Overview

6.6.3 Teva Pharmaceutical Industries Ltd Endothelin Antagonists Therapeutics Sales, Revenue and Gross Margin (2019-2024)

6.4.4 Teva Pharmaceutical Industries Ltd Endothelin Antagonists Therapeutics Product Portfolio

6.7.5 Teva Pharmaceutical Industries Ltd Recent Developments/Updates

6.8 Sigmapharm Laboratories , LLC

6.8.1 Sigmapharm Laboratories , LLC Corporation Information

6.8.2 Sigmapharm Laboratories , LLC Description and Business Overview

6.8.3 Sigmapharm Laboratories , LLC Endothelin Antagonists Therapeutics Sales, Revenue and Gross Margin (2019-2024)

6.8.4 Sigmapharm Laboratories , LLC Endothelin Antagonists Therapeutics Product Portfolio

6.8.5 Sigmapharm Laboratories , LLC Recent Developments/Updates

6.9 Alembic Pharmaceuticals Limited

6.9.1 Alembic Pharmaceuticals Limited Corporation Information

6.9.2 Alembic Pharmaceuticals Limited Description and Business Overview

6.9.3 Alembic Pharmaceuticals Limited Endothelin Antagonists Therapeutics Sales, Revenue and Gross Margin (2019-2024)

6.9.4 Alembic Pharmaceuticals Limited Endothelin Antagonists Therapeutics Product Portfolio

6.9.5 Alembic Pharmaceuticals Limited Recent Developments/Updates

6.10 Hikma Pharmaceuticals PLC

6.10.1 Hikma Pharmaceuticals PLC Corporation Information

6.10.2 Hikma Pharmaceuticals PLC Description and Business Overview

6.10.3 Hikma Pharmaceuticals PLC Endothelin Antagonists Therapeutics Sales, Revenue and Gross Margin (2019-2024)

6.10.4 Hikma Pharmaceuticals PLC Endothelin Antagonists Therapeutics Product Portfolio

6.10.5 Hikma Pharmaceuticals PLC Recent Developments/Updates

6.11 Amneal Pharmaceuticals LLC

6.11.1 Amneal Pharmaceuticals LLC Corporation Information

6.11.2 Amneal Pharmaceuticals LLC Endothelin Antagonists Therapeutics Description and Business Overview

6.11.3 Amneal Pharmaceuticals LLC Endothelin Antagonists Therapeutics Sales, Revenue and Gross Margin (2019-2024)

6.11.4 Amneal Pharmaceuticals LLC Endothelin Antagonists Therapeutics Product Portfolio

6.11.5 Amneal Pharmaceuticals LLC Recent Developments/Updates

6.12 AstraZeneca

6.12.1 AstraZeneca Corporation Information

6.12.2 AstraZeneca Endothelin Antagonists Therapeutics Description and Business Overview

6.12.3 AstraZeneca Endothelin Antagonists Therapeutics Sales, Revenue and Gross Margin (2019-2024)

6.12.4 AstraZeneca Endothelin Antagonists Therapeutics Product Portfolio

6.12.5 AstraZeneca Recent Developments/Updates

6.13 Johnsons & Johnsons Private limited

6.13.1 Johnsons & Johnsons Private limited Corporation Information

6.13.2 Johnsons & Johnsons Private limited Endothelin Antagonists Therapeutics Description and Business Overview

6.13.3 Johnsons & Johnsons Private limited Endothelin Antagonists Therapeutics Sales, Revenue and Gross Margin (2019-2024)

6.13.4 Johnsons & Johnsons Private limited Endothelin Antagonists Therapeutics Product Portfolio

6.13.5 Johnsons & Johnsons Private limited Recent Developments/Updates

6.14 GSK Plc

6.14.1 GSK Plc Corporation Information

6.14.2 GSK Plc Endothelin Antagonists Therapeutics Description and Business Overview

6.14.3 GSK Plc Endothelin Antagonists Therapeutics Sales, Revenue and Gross Margin (2019-2024)

6.14.4 GSK Plc Endothelin Antagonists Therapeutics Product Portfolio

6.14.5 GSK Plc Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Endothelin Antagonists Therapeutics Industry Chain Analysis

7.2 Endothelin Antagonists Therapeutics Key Raw Materials

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Endothelin Antagonists Therapeutics Production Mode & Process

7.4 Endothelin Antagonists Therapeutics Sales and Marketing

7.4.1 Endothelin Antagonists Therapeutics Sales Channels

7.4.2 Endothelin Antagonists Therapeutics Distributors

7.5 Endothelin Antagonists Therapeutics Customers

8 Endothelin Antagonists Therapeutics Market Dynamics

8.1 Endothelin Antagonists Therapeutics Industry Trends

8.2 Endothelin Antagonists Therapeutics Market Drivers

8.3 Endothelin Antagonists Therapeutics Market Challenges

8.4 Endothelin Antagonists Therapeutics Market Restraints

9 Research Finding and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Gilead Sciences Inc

Sun Pharmaceutical Industries Ltd.

Lupin Ltd

Zydus Group

Endo International Plc.

Mylan NV

Teva Pharmaceutical Industries Ltd

Sigmapharm Laboratories LLC

Alembic Pharmaceuticals Limited

Hikma Pharmaceuticals PLC

Amneal Pharmaceuticals LLC

Astrazeneca plc

GSK

Johnsons & Johnsons Private limited

List of Tables

Table 1. Global Endothelin Antagonists Therapeutics Market Value Comparison by Type (2024-2030) & (US$ Million)

Table 2. Global Endothelin Antagonists Therapeutics Market Value Comparison by Application (2024-2030) & (US$ Million)

Table 3. Global Endothelin Antagonists Therapeutics Market Competitive Situation by Manufacturers in 2023

Table 4. Global Endothelin Antagonists Therapeutics Sales (K Units) of Key Manufacturers (2019-2024)

Table 5. Global Endothelin Antagonists Therapeutics Sales Market Share by Manufacturers (2019-2024)

Table 6. Global Endothelin Antagonists Therapeutics Revenue (US$ Million) by Manufacturers (2019-2024)

Table 7. Global Endothelin Antagonists Therapeutics Revenue Share by Manufacturers (2019-2024)

Table 8. Global Market Endothelin Antagonists Therapeutics Average Price (US$/Unit) of Key Manufacturers (2019-2024)

Table 9. Global Key Players of Endothelin Antagonists Therapeutics, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Endothelin Antagonists Therapeutics, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Endothelin Antagonists Therapeutics, Product Type & Application

Table 12. Global Key Manufacturers of Endothelin Antagonists Therapeutics, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Endothelin Antagonists Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Endothelin Antagonists Therapeutics as of 2023)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Endothelin Antagonists Therapeutics Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 17. Global Endothelin Antagonists Therapeutics Sales by Region (2019-2024) & (K Units)

Table 18. Global Endothelin Antagonists Therapeutics Sales Market Share by Region (2019-2024)

Table 19. Global Endothelin Antagonists Therapeutics Sales by Region (2025-2030) & (K Units)

Table 20. Global Endothelin Antagonists Therapeutics Sales Market Share by Region (2025-2030)

Table 21. Global Endothelin Antagonists Therapeutics Revenue by Region (2019-2024) & (US$ Million)

Table 22. Global Endothelin Antagonists Therapeutics Revenue Market Share by Region (2019-2024)

Table 23. Global Endothelin Antagonists Therapeutics Revenue by Region (2025-2030) & (US$ Million)

Table 24. Global Endothelin Antagonists Therapeutics Revenue Market Share by Region (2025-2030)

Table 25. North America Endothelin Antagonists Therapeutics Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 26. North America Endothelin Antagonists Therapeutics Sales by Country (2019-2024) & (K Units)

Table 27. North America Endothelin Antagonists Therapeutics Sales by Country (2025-2030) & (K Units)

Table 28. North America Endothelin Antagonists Therapeutics Revenue by Country (2019-2024) & (US$ Million)

Table 29. North America Endothelin Antagonists Therapeutics Revenue by Country (2025-2030) & (US$ Million)

Table 30. Europe Endothelin Antagonists Therapeutics Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 31. Europe Endothelin Antagonists Therapeutics Sales by Country (2019-2024) & (K Units)

Table 32. Europe Endothelin Antagonists Therapeutics Sales by Country (2025-2030) & (K Units)

Table 33. Europe Endothelin Antagonists Therapeutics Revenue by Country (2019-2024) & (US$ Million)

Table 34. Europe Endothelin Antagonists Therapeutics Revenue by Country (2025-2030) & (US$ Million)

Table 35. Asia Pacific Endothelin Antagonists Therapeutics Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 36. Asia Pacific Endothelin Antagonists Therapeutics Sales by Region (2019-2024) & (K Units)

Table 37. Asia Pacific Endothelin Antagonists Therapeutics Sales by Region (2025-2030) & (K Units)

Table 38. Asia Pacific Endothelin Antagonists Therapeutics Revenue by Region (2019-2024) & (US$ Million)

Table 39. Asia Pacific Endothelin Antagonists Therapeutics Revenue by Region (2025-2030) & (US$ Million)

Table 40. Latin America Endothelin Antagonists Therapeutics Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Latin America Endothelin Antagonists Therapeutics Sales by Country (2019-2024) & (K Units)

Table 42. Latin America Endothelin Antagonists Therapeutics Sales by Country (2025-2030) & (K Units)

Table 43. Latin America Endothelin Antagonists Therapeutics Revenue by Country (2019-2024) & (US$ Million)

Table 44. Latin America Endothelin Antagonists Therapeutics Revenue by Country (2025-2030) & (US$ Million)

Table 45. Middle East & Africa Endothelin Antagonists Therapeutics Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 46. Middle East & Africa Endothelin Antagonists Therapeutics Sales by Country (2019-2024) & (K Units)

Table 47. Middle East & Africa Endothelin Antagonists Therapeutics Sales by Country (2025-2030) & (K Units)

Table 48. Middle East & Africa Endothelin Antagonists Therapeutics Revenue by Country (2019-2024) & (US$ Million)

Table 49. Middle East & Africa Endothelin Antagonists Therapeutics Revenue by Country (2025-2030) & (US$ Million)

Table 50. Global Endothelin Antagonists Therapeutics Sales (K Units) by Type (2019-2024)

Table 51. Global Endothelin Antagonists Therapeutics Sales (K Units) by Type (2025-2030)

Table 52. Global Endothelin Antagonists Therapeutics Sales Market Share by Type (2019-2024)

Table 53. Global Endothelin Antagonists Therapeutics Sales Market Share by Type (2025-2030)

Table 54. Global Endothelin Antagonists Therapeutics Revenue (US$ Million) by Type (2019-2024)

Table 55. Global Endothelin Antagonists Therapeutics Revenue (US$ Million) by Type (2025-2030)

Table 56. Global Endothelin Antagonists Therapeutics Revenue Market Share by Type (2019-2024)

Table 57. Global Endothelin Antagonists Therapeutics Revenue Market Share by Type (2025-2030)

Table 58. Global Endothelin Antagonists Therapeutics Price (US$/Unit) by Type (2019-2024)

Table 59. Global Endothelin Antagonists Therapeutics Price (US$/Unit) by Type (2025-2030)

Table 60. Global Endothelin Antagonists Therapeutics Sales (K Units) by Application (2019-2024)

Table 61. Global Endothelin Antagonists Therapeutics Sales (K Units) by Application (2025-2030)

Table 62. Global Endothelin Antagonists Therapeutics Sales Market Share by Application (2019-2024)

Table 63. Global Endothelin Antagonists Therapeutics Sales Market Share by Application (2025-2030)

Table 64. Global Endothelin Antagonists Therapeutics Revenue (US$ Million) by Application (2019-2024)

Table 65. Global Endothelin Antagonists Therapeutics Revenue (US$ Million) by Application (2025-2030)

Table 66. Global Endothelin Antagonists Therapeutics Revenue Market Share by Application (2019-2024)

Table 67. Global Endothelin Antagonists Therapeutics Revenue Market Share by Application (2025-2030)

Table 68. Global Endothelin Antagonists Therapeutics Price (US$/Unit) by Application (2019-2024)

Table 69. Global Endothelin Antagonists Therapeutics Price (US$/Unit) by Application (2025-2030)

Table 70. Gilead Sciences, Inc Corporation Information

Table 71. Gilead Sciences, Inc Description and Business Overview

Table 72. Gilead Sciences, Inc Endothelin Antagonists Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 73. Gilead Sciences, Inc Endothelin Antagonists Therapeutics Product

Table 74. Gilead Sciences, Inc Recent Developments/Updates

Table 75. Sun Pharmaceutical Industries Ltd Corporation Information

Table 76. Sun Pharmaceutical Industries Ltd Description and Business Overview

Table 77. Sun Pharmaceutical Industries Ltd Endothelin Antagonists Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 78. Sun Pharmaceutical Industries Ltd Endothelin Antagonists Therapeutics Product

Table 79. Sun Pharmaceutical Industries Ltd Recent Developments/Updates

Table 80. Lupin Corporation Information

Table 81. Lupin Description and Business Overview

Table 82. Lupin Endothelin Antagonists Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 83. Lupin Endothelin Antagonists Therapeutics Product

Table 84. Lupin Recent Developments/Updates

Table 85. Zydus Group Corporation Information

Table 86. Zydus Group Description and Business Overview

Table 87. Zydus Group Endothelin Antagonists Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 88. Zydus Group Endothelin Antagonists Therapeutics Product

Table 89. Zydus Group Recent Developments/Updates

Table 90. Endo International plc Corporation Information

Table 91. Endo International plc Description and Business Overview

Table 92. Endo International plc Endothelin Antagonists Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 93. Endo International plc Endothelin Antagonists Therapeutics Product

Table 94. Endo International plc Recent Developments/Updates

Table 95. Mylan NV Corporation Information

Table 96. Mylan NV Description and Business Overview

Table 97. Mylan NV Endothelin Antagonists Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 98. Mylan NV Endothelin Antagonists Therapeutics Product

Table 99. Mylan NV Recent Developments/Updates

Table 100. Teva Pharmaceutical Industries Ltd Corporation Information

Table 101. Teva Pharmaceutical Industries Ltd Description and Business Overview

Table 102. Teva Pharmaceutical Industries Ltd Endothelin Antagonists Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 103. Teva Pharmaceutical Industries Ltd Endothelin Antagonists Therapeutics Product

Table 104. Teva Pharmaceutical Industries Ltd Recent Developments/Updates

Table 105. Sigmapharm Laboratories , LLC Corporation Information

Table 106. Sigmapharm Laboratories , LLC Description and Business Overview

Table 107. Sigmapharm Laboratories , LLC Endothelin Antagonists Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 108. Sigmapharm Laboratories , LLC Endothelin Antagonists Therapeutics Product

Table 109. Sigmapharm Laboratories , LLC Recent Developments/Updates

Table 110. Alembic Pharmaceuticals Limited Corporation Information

Table 111. Alembic Pharmaceuticals Limited Description and Business Overview

Table 112. Alembic Pharmaceuticals Limited Endothelin Antagonists Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 113. Alembic Pharmaceuticals Limited Endothelin Antagonists Therapeutics Product

Table 114. Alembic Pharmaceuticals Limited Recent Developments/Updates

Table 115. Hikma Pharmaceuticals PLC Corporation Information

Table 116. Hikma Pharmaceuticals PLC Description and Business Overview

Table 117. Hikma Pharmaceuticals PLC Endothelin Antagonists Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 118. Hikma Pharmaceuticals PLC Endothelin Antagonists Therapeutics Product

Table 119. Hikma Pharmaceuticals PLC Recent Developments/Updates

Table 120. Amneal Pharmaceuticals LLC Corporation Information

Table 121. Amneal Pharmaceuticals LLC Description and Business Overview

Table 122. Amneal Pharmaceuticals LLC Endothelin Antagonists Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 123. Amneal Pharmaceuticals LLC Endothelin Antagonists Therapeutics Product

Table 124. Amneal Pharmaceuticals LLC Recent Developments/Updates

Table 125. AstraZeneca Corporation Information

Table 126. AstraZeneca Description and Business Overview

Table 127. AstraZeneca Endothelin Antagonists Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 128. AstraZeneca Endothelin Antagonists Therapeutics Product

Table 129. AstraZeneca Recent Developments/Updates

Table 130. Johnsons & Johnsons Private limited Corporation Information

Table 131. Johnsons & Johnsons Private limited Description and Business Overview

Table 132. Johnsons & Johnsons Private limited Endothelin Antagonists Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 133. Johnsons & Johnsons Private limited Endothelin Antagonists Therapeutics Product

Table 134. Johnsons & Johnsons Private limited Recent Developments/Updates

Table 135. GSK Plc Corporation Information

Table 136. GSK Plc Description and Business Overview

Table 137. GSK Plc Endothelin Antagonists Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 138. GSK Plc Endothelin Antagonists Therapeutics Product

Table 139. GSK Plc Recent Developments/Updates

Table 140. Key Raw Materials Lists

Table 141. Raw Materials Key Suppliers Lists

Table 142. Endothelin Antagonists Therapeutics Distributors List

Table 143. Endothelin Antagonists Therapeutics Customers List

Table 144. Endothelin Antagonists Therapeutics Market Trends

Table 145. Endothelin Antagonists Therapeutics Market Drivers

Table 146. Endothelin Antagonists Therapeutics Market Challenges

Table 147. Endothelin Antagonists Therapeutics Market Restraints

Table 148. Research Programs/Design for This Report

Table 149. Key Data Information from Secondary Sources

Table 150. Key Data Information from Primary Sources

List of Figures

Figure 1. Product Picture of Endothelin Antagonists Therapeutics

Figure 2. Global Endothelin Antagonists Therapeutics Market Value Comparison by Type (2024-2030) & (US$ Million)

Figure 3. Global Endothelin Antagonists Therapeutics Market Share by Type in 2023 & 2030

Figure 4. Oral Product Picture

Figure 5. Parenteral Product Picture

Figure 6. Global Endothelin Antagonists Therapeutics Market Value Comparison by Application (2024-2030) & (US$ Million)

Figure 7. Global Endothelin Antagonists Therapeutics Market Share by Application in 2023 & 2030

Figure 8. Cardiovascular Diseases

Figure 9. Scleroderma

Figure 10. Other

Figure 11. Global Endothelin Antagonists Therapeutics Revenue, (US$ Million), 2019 VS 2023 VS 2030

Figure 12. Global Endothelin Antagonists Therapeutics Market Size (2019-2030) & (US$ Million)

Figure 13. Global Endothelin Antagonists Therapeutics Sales (2019-2030) & (K Units)

Figure 14. Global Endothelin Antagonists Therapeutics Average Price (US$/Unit) & (2019-2030)

Figure 15. Endothelin Antagonists Therapeutics Report Years Considered

Figure 16. Endothelin Antagonists Therapeutics Sales Share by Manufacturers in 2023

Figure 17. Global Endothelin Antagonists Therapeutics Revenue Share by Manufacturers in 2023

Figure 18. The Global 5 and 10 Largest Endothelin Antagonists Therapeutics Players: Market Share by Revenue in 2023

Figure 19. Endothelin Antagonists Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023

Figure 20. Global Endothelin Antagonists Therapeutics Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Figure 21. North America Endothelin Antagonists Therapeutics Sales Market Share by Country (2019-2030)

Figure 22. North America Endothelin Antagonists Therapeutics Revenue Market Share by Country (2019-2030)

Figure 23. United States Endothelin Antagonists Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 24. Canada Endothelin Antagonists Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 25. Europe Endothelin Antagonists Therapeutics Sales Market Share by Country (2019-2030)

Figure 26. Europe Endothelin Antagonists Therapeutics Revenue Market Share by Country (2019-2030)

Figure 27. Germany Endothelin Antagonists Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 28. France Endothelin Antagonists Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 29. U.K. Endothelin Antagonists Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 30. Italy Endothelin Antagonists Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 31. Russia Endothelin Antagonists Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 32. Asia Pacific Endothelin Antagonists Therapeutics Sales Market Share by Region (2019-2030)

Figure 33. Asia Pacific Endothelin Antagonists Therapeutics Revenue Market Share by Region (2019-2030)

Figure 34. China Endothelin Antagonists Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 35. Japan Endothelin Antagonists Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 36. South Korea Endothelin Antagonists Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 37. India Endothelin Antagonists Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 38. Australia Endothelin Antagonists Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 39. China Taiwan Endothelin Antagonists Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 40. Southeast Asia Endothelin Antagonists Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 41. Latin America Endothelin Antagonists Therapeutics Sales Market Share by Country (2019-2030)

Figure 42. Latin America Endothelin Antagonists Therapeutics Revenue Market Share by Country (2019-2030)

Figure 43. Mexico Endothelin Antagonists Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 44. Brazil Endothelin Antagonists Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 45. Argentina Endothelin Antagonists Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 46. Middle East & Africa Endothelin Antagonists Therapeutics Sales Market Share by Country (2019-2030)

Figure 47. Middle East & Africa Endothelin Antagonists Therapeutics Revenue Market Share by Country (2019-2030)

Figure 48. Turkey Endothelin Antagonists Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 49. Saudi Arabia Endothelin Antagonists Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 50. UAE Endothelin Antagonists Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 51. Global Sales Market Share of Endothelin Antagonists Therapeutics by Type (2019-2030)

Figure 52. Global Revenue Market Share of Endothelin Antagonists Therapeutics by Type (2019-2030)

Figure 53. Global Endothelin Antagonists Therapeutics Price (US$/Unit) by Type (2019-2030)

Figure 54. Global Sales Market Share of Endothelin Antagonists Therapeutics by Application (2019-2030)

Figure 55. Global Revenue Market Share of Endothelin Antagonists Therapeutics by Application (2019-2030)

Figure 56. Global Endothelin Antagonists Therapeutics Price (US$/Unit) by Application (2019-2030)

Figure 57. Endothelin Antagonists Therapeutics Value Chain

Figure 58. Endothelin Antagonists Therapeutics Production Process

Figure 59. Channels of Distribution (Direct Vs Distribution)

Figure 60. Distributors Profiles

Figure 61. Bottom-up and Top-down Approaches for This Report

Figure 62. Data Triangulation

Figure 63. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions